CA2702340C - Compositions et procedes destines a moduler des reponses immunes - Google Patents

Compositions et procedes destines a moduler des reponses immunes Download PDF

Info

Publication number
CA2702340C
CA2702340C CA2702340A CA2702340A CA2702340C CA 2702340 C CA2702340 C CA 2702340C CA 2702340 A CA2702340 A CA 2702340A CA 2702340 A CA2702340 A CA 2702340A CA 2702340 C CA2702340 C CA 2702340C
Authority
CA
Canada
Prior art keywords
antigen
use according
inhibitor
epub
dna binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2702340A
Other languages
English (en)
Other versions
CA2702340A1 (fr
Inventor
Ranjeny Thomas
Brendan John O'sullivan
Nigel Meredith Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006905674A external-priority patent/AU2006905674A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CA2702340A1 publication Critical patent/CA2702340A1/fr
Application granted granted Critical
Publication of CA2702340C publication Critical patent/CA2702340C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Abstract

La présente invention concerne des procédés et des compositions destinés à moduler des réponses immunes, qui impliquent l'administration particulaire d'agents à des cellules immunes, lesdits agents comprenant un inhibiteur de la voie de signalisation NF-?B et un antigène qui correspond à un antigène cible. Les procédés et les compositions de la présente invention sont particulièrement utiles dans le traitement ou la prophylaxie d'une réponse immune indésirable associée à l'antigène cible, incluant les maladies auto-immunes, les allergies et les maladies associées aux transplantations.
CA2702340A 2006-10-12 2007-10-12 Compositions et procedes destines a moduler des reponses immunes Active CA2702340C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2006905674 2006-10-12
AU2006905674A AU2006905674A0 (en) 2006-10-12 Compositions and methods for modulating immune responses
US85381406P 2006-10-24 2006-10-24
US60/853,814 2006-10-24
PCT/AU2007/001555 WO2008043157A1 (fr) 2006-10-12 2007-10-12 Compositions et procédés destinés à moduler des réponses immunes

Publications (2)

Publication Number Publication Date
CA2702340A1 CA2702340A1 (fr) 2008-04-17
CA2702340C true CA2702340C (fr) 2014-12-16

Family

ID=39282363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702340A Active CA2702340C (fr) 2006-10-12 2007-10-12 Compositions et procedes destines a moduler des reponses immunes

Country Status (6)

Country Link
US (2) US9017697B2 (fr)
EP (2) EP2077821B1 (fr)
JP (1) JP2010505883A (fr)
AU (1) AU2007306936B2 (fr)
CA (1) CA2702340C (fr)
WO (1) WO2008043157A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6993506B2 (en) 2000-12-05 2006-01-31 Jgr Acquisition, Inc. Method and device utilizing polymorphic data in e-commerce
WO2007001448A2 (fr) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques
WO2007070660A2 (fr) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Echafaudages pour transplantation cellulaire
WO2007070682A2 (fr) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology Systeme de criblage de particules
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2077821B1 (fr) 2006-10-12 2019-08-14 The University Of Queensland Compositions et procédés destinés à moduler des réponses immunes
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
WO2009132277A1 (fr) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition de la néovascularisation par des nanoparticules d'oxyde de cérium
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
AU2010254550B2 (en) 2009-05-27 2015-10-15 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
JP5926180B2 (ja) * 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
EP2501372A4 (fr) * 2009-11-19 2013-04-10 Signpath Pharma Inc Infusion intraveineuse de curcumine et de bloqueur des canaux calciques
US8697086B2 (en) * 2010-01-19 2014-04-15 Chieh-Chou Yu Use of Antrodia camphorata for treating diseases
US9393198B2 (en) * 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
JP2011231045A (ja) * 2010-04-27 2011-11-17 Kansai Medical Univ インターフェロン関与自己免疫疾患抑制剤
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
JPWO2011152503A1 (ja) 2010-06-02 2013-08-01 大日本住友製薬株式会社 自己免疫疾患またはアレルギー疾患の治療剤
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US8877207B2 (en) 2010-09-17 2014-11-04 University Of Central Florida Research Foundation, Inc. Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods
KR101331784B1 (ko) * 2010-09-27 2013-11-21 한국생명공학연구원 화학식 1 내지 8로 표시되는 화합물 또는 고삼 추출물을 유효성분으로 포함하는 면역 증강용 조성물
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
JP5909745B2 (ja) 2010-11-12 2016-04-27 クール ファーマシューティカルズ ディベロップメント カンパニー 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬
WO2012082803A2 (fr) 2010-12-13 2012-06-21 Cel-Sci Corporation Procédé pour induire une réponse immunitaire contre les virus de la grippe aviaire, porcine, espagnole, h1n1, h5n9 et leurs formulations
PL226015B1 (pl) * 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
WO2012149393A2 (fr) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Nanovecteurs synthétiques tolérogènes destinés à une délétion, spécifique à un antigène, de cellules effectrices
WO2012162564A1 (fr) 2011-05-25 2012-11-29 Cel-Sci Corporation Procédé d'induction d'une réponse immunitaire et formulations afférentes
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
AU2012290306B2 (en) 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
US20140207105A1 (en) * 2011-08-31 2014-07-24 Perosphere, Inc. Methods for Effectively and Rapidly Desensitizing Allergic Patients
US20130058902A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
WO2013060328A1 (fr) 2011-10-26 2013-05-02 Herlev Hospital IMMUNOTHÉRAPIE BASÉE SUR IkB
CN104519907A (zh) * 2012-03-23 2015-04-15 昆士兰大学 免疫调节剂及其用途
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
AU2013278056B2 (en) 2012-06-21 2018-07-05 Northwestern University Peptide conjugated particles
WO2014036534A1 (fr) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumine-er, nanocurcumine liposomale à liberation prolongée-plga pour réduire au minimum la prolongation du qt dans les thérapies anticancéreuses
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
KR20160014584A (ko) 2013-03-13 2016-02-11 코어 파마슈티칼스 디벨롭먼트 컴퍼니 염증 치료용 면역-변형된 입자
WO2014179771A1 (fr) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Associations de dosages destinées à réduire les réponses immunitaires à médiation humorale non souhaitées
EA201592103A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Способы и композиции для усиления cd4+ регуляторных t-клеток
AU2014274894A1 (en) 2013-06-04 2015-11-26 Selecta Biosciences, Inc. Repeated administration of non-immunosupressive antigen specific immunotherapeutics
ES2762187T3 (es) 2013-08-13 2020-05-22 Univ Northwestern Partículas conjugadas con péptidos
US9603882B2 (en) * 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP3431493A1 (fr) * 2013-09-03 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions et procédés permettant d'induire la sénescence de cancer
US20150147385A1 (en) * 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
BR112016019274A2 (pt) 2014-02-21 2017-10-10 Anokion Sa agentes terapêuticos glico-orientados
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3137105A4 (fr) 2014-04-30 2017-12-27 President and Fellows of Harvard College Dispositifs de vaccin combiné et procédés de destruction de cellules cancéreuses
WO2016037163A1 (fr) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Procédés et compositions pour atténuer des réponses immunitaires contre des vecteurs de transfert viraux pour la thérapie génique
JP2018501322A (ja) * 2015-01-12 2018-01-18 チルドレンズ メディカル センター コーポレーション トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
EP3250250A4 (fr) 2015-01-30 2019-05-22 President and Fellows of Harvard College Matériaux péritumoraux et intratumoraux pour traitement anticancéreux
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
WO2016172069A1 (fr) * 2015-04-20 2016-10-27 Washington State University Méthodes de traitement de maladies des voies respiratoires associées à une inflammation et infections virales
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
US11266642B2 (en) 2015-12-22 2022-03-08 Icahn School Of Medicine At Mount Sinai Small molecule inhibitors of HLA-DR3 binding for treating autoimmune thyroiditis
EP3411475A4 (fr) 2016-02-06 2019-09-11 President and Fellows of Harvard College Régénération de la niche hématopoïétique pour reconstituer l'immunité
WO2017147318A1 (fr) 2016-02-23 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Compositions et procédés pour préparer et utiliser des formulations immunogènes thermostables présentant une compatibilité accrue d'utilisation comme vaccins contre un ou plusieurs agents pathogènes
KR101776001B1 (ko) 2016-03-04 2017-09-07 (주)뉴트리 판두라틴 또는 핑거루트(보에센베르기아 판두라타) 추출물을 포함하는 골 손실 질환 치료, 예방 또는 개선용 조성물
EP3448374A4 (fr) 2016-04-27 2020-01-08 Signpath Pharma Inc. Prévention d'un bloc atrio-ventriculaire induit par des médicaments
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN106421777A (zh) * 2016-10-19 2017-02-22 广西大学 白藜芦醇作为疫苗佐剂的应用
WO2018169811A1 (fr) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Procédés et compositions associés à un traitement combiné avec anti-inflammatoires et nanovecteurs synthétiques comprenant un immunosuppresseur
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
CN111315358A (zh) 2017-08-28 2020-06-19 环球生物生命有限公司 预防和治疗病毒感染的方法和组合物
KR20200105678A (ko) * 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
WO2020118159A1 (fr) * 2018-12-07 2020-06-11 The University Of Chicago Méthodes et compositions comportant un inhibiteur de nf-kb et un adjuvant
JP2022519817A (ja) 2019-01-23 2022-03-25 ビフォー ブランズ，インコーポレイテッド 混合アレルゲン組成物の製造方法
CN111297814A (zh) * 2019-12-18 2020-06-19 湖南千金协力药业有限公司 一种降低雷公藤多苷片肝毒性的复方制剂及其制备方法
CN111514115A (zh) * 2020-04-26 2020-08-11 天津大学 一种自身免疫性肝炎治疗纳米颗粒的合成方法
WO2021232052A1 (fr) * 2020-05-11 2021-11-18 Texas Biomedical Research Institute Système d'administration microencapsulé pour la libération d'agents anti-inflammatoires dans le poumon
US20230255970A1 (en) * 2020-08-12 2023-08-17 The Broad Institute, Inc. Compositions and methods for treating proliferative diseases
CN112079911B (zh) * 2020-09-04 2022-04-08 扬州大学 一种促进银杏类黄酮合成的关键基因GbMYB6及其表达的蛋白、载体和应用
CN112675299B (zh) * 2021-01-06 2023-10-20 黑龙江省百洲生物工程有限公司 一种防控鹅星状病毒复合佐剂灭活疫苗的制备方法
BR112023025692A2 (pt) * 2021-06-22 2024-02-27 Fujifilm Irvine Scient Inc Método e uso de uma linhagem de camundongo transgênico
WO2023086806A1 (fr) * 2021-11-09 2023-05-19 The University Of Chicago Compositions et méthodes pour induire une tolérance immunitaire
CN114134104A (zh) * 2021-11-30 2022-03-04 吉林医药学院 虾青素在制备缓解卵泡氧化应激损伤的药物中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1590574A (en) 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
ES2053549T3 (es) 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5120657A (en) 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
CA2073045C (fr) 1989-11-03 2007-05-22 Malcolm L. Gefter Proteine feline reagissant avec les lymphocytes t humains isolee de la poussiere domestique et les utilisations de cette proteine
JP3359919B2 (ja) 1990-05-16 2002-12-24 サザン・リサーチ・インスティテュート 放出制御ドーパミンおよび神経線維成長を刺激するための用途
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB9016885D0 (en) 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1994024281A1 (fr) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation Epitopes de lymphocytes t des principaux allergenes de dermatophagoides (acariens detriticoles)
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
MX9702357A (es) 1994-09-29 1997-06-28 Andaris Ltd Microparticulas secadas por aspersion como vehiculos terapeuticos.
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
HU227939B1 (en) 1996-05-29 2012-06-28 Delsitech Oy Dissolvable oxides for biological applications
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
EP0888790A1 (fr) 1997-07-04 1999-01-07 PowderJect Research Limited Appareil d'apport de particules medicamenteuses
WO1999029865A2 (fr) 1997-12-12 1999-06-17 The Rockefeller University Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US20020142974A1 (en) 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
PT1117382E (pt) 1998-10-01 2005-08-31 Powderject Res Ltd Microparticulas revestidas por pulverizacao para utilizacao em seringas sem agulha
EP1119630B1 (fr) 1998-11-05 2006-01-11 Powderject Vaccines, Inc. Produits de recombinaison d'acide nucleique pour immunisation genetique
ATE368011T1 (de) 1999-02-22 2007-08-15 Delsitech Oy Biologisch abbaubaren keramischen fasern aus kiselsäuresol
WO2000061132A1 (fr) 1999-04-14 2000-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions contenant des immunotoxines et des agents inhibiteurs de maturation de cellule dendritique permettant d'induire une tolerance immunitaire dans une greffe
CA2370646A1 (fr) 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Immunisation de l'acide nucleique
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
AU2001252390A1 (en) 2000-05-01 2001-11-12 Powderject Vaccines, Inc. Nucleic acid immunization
EP1289494A2 (fr) 2000-06-08 2003-03-12 Powderject Vaccines, Inc. Compositions de poudre
US20020051821A1 (en) 2000-09-08 2002-05-02 Sung-Yun Kwon Aliginate particle formulation
EP1392365A2 (fr) 2000-11-02 2004-03-03 Powderject Vaccines, Inc. Compositions et utilisation therapeutique de polynucleotides codant pour le tcr
EP1399132A1 (fr) 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Production de particules dures, denses
EP1399131A2 (fr) 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Compositions lyophilisees de pulverisation
WO2003000199A2 (fr) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Compositions et procedes associes a l'ilt3 et l'ilt4
WO2004013302A2 (fr) 2002-08-02 2004-02-12 Phenomix, Inc. Polypeptides activant card11 nfkb, acides nucleiques, animaux non croises et transgeniques, et procedes d'utilisation associes
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor
WO2004017943A2 (fr) 2002-08-23 2004-03-04 Medigene Oncology Gmbh Formulations lipidiques cationiques non vesiculaires
CA2501940A1 (fr) 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferablement associees aux cellules t effectrices ou aux cellules t regulatrices et procedes d'utilisation de ces molecules
JP2006508191A (ja) 2002-11-08 2006-03-09 トーラーレックス， インク． エフェクタｔ細胞に優先的に関連する分子及びそれらの使用法
NZ541793A (en) 2003-01-24 2008-11-28 Univ New York State Res Found Ceramic based nanoparticles for entrapping photosensitive drug/dye for photodynamic therapy
US7052147B2 (en) * 2003-02-20 2006-05-30 Seiko Epson Corporation Light source, and projector provided with the light source
US20040166095A1 (en) 2003-02-25 2004-08-26 Blazar Bruce R. Methods for preventing GVHD
US20050208036A1 (en) 2003-02-25 2005-09-22 University Of North Carolina At Chapel Hill Methods for treating or preventing GVHD
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
EP1462111A1 (fr) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Composition pour l'induction d'immunotolérance
EP1462114A1 (fr) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Procédés et moyens pour opprimer les symptomes d'une maladie allergique par inhibition du récepteur du facteur de nécrose tumorale inductible par les glucocorticoides (GRIT ou TNFRSF18)
US7910523B2 (en) 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
EP1547581A1 (fr) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Vaccin liposomal pour le traitement de maladies malignes humaines et hematologiques
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
DE102004016089B4 (de) 2004-04-01 2012-12-06 Deere & Company Einrichtung zur Verstellung der Position einer Gegenschneide gegenüber einer Häckseleinrichtung
WO2005099751A2 (fr) 2004-04-01 2005-10-27 Alza Corporation Appareil et methode d'administration par voie transdermique d'un vaccin contre la grippe
US20050260260A1 (en) 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
CA2599951A1 (fr) 2005-03-04 2006-09-14 Altairnano, Inc. Structures ceramiques pour liberation controlee de substances actives sur le plan biologique
EP2077821B1 (fr) 2006-10-12 2019-08-14 The University Of Queensland Compositions et procédés destinés à moduler des réponses immunes

Also Published As

Publication number Publication date
AU2007306936A1 (en) 2008-04-17
CA2702340A1 (fr) 2008-04-17
EP3590503A1 (fr) 2020-01-08
EP2077821B1 (fr) 2019-08-14
JP2010505883A (ja) 2010-02-25
AU2007306936B2 (en) 2014-02-06
US9561272B2 (en) 2017-02-07
EP2077821A1 (fr) 2009-07-15
US20150202285A1 (en) 2015-07-23
WO2008043157A1 (fr) 2008-04-17
US9017697B2 (en) 2015-04-28
EP2077821A4 (fr) 2015-06-10
US20100151000A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
US9561272B2 (en) Compositions and methods for modulating immune responses
CN101646418B (zh) 调节免疫应答的组合物和方法
Silva et al. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation
EP2827890B1 (fr) Agent immunomodulateur et ses utilisations
Cibulski et al. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake
Wusiman et al. Immunomodulatory effects of Alhagi honey polysaccharides encapsulated into PLGA nanoparticles
Badiee et al. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends
Capini et al. Antigen-specific suppression of inflammatory arthritis using liposomes
Mueller et al. Tumor eradication by immunotherapy with biodegradable PLGA microspheres—an alternative to incomplete Freund's adjuvant
US11160861B2 (en) Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
US11065330B2 (en) Induction of antigen-specific tolerance by peripheral phagocytosis
Ojiako et al. Preliminary studies on the formulation of immune stimulating complexes using saponin from Carica papaya leaves
Feng et al. DEC-205 receptor-mediated long-circling nanoliposome as an antigen and Eucommia ulmoides polysaccharide delivery system enhances the immune response via facilitating dendritic cells maturation
Oghumu et al. Pentalinonsterol, a constituent of pentalinon andrieuxii, possesses potent immunomodulatory activity and primes t cell immune responses
Tafaghodi et al. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
US20230285529A1 (en) Immunostimulatory compositions comprising soluble parasite extracts and uses thereof
Feng et al. DEC-205 receptor targeted poly (lactic-co-glycolic acid) nanoparticles containing Eucommia ulmoides polysaccharide enhances the immune response of foot-and-mouth disease vaccine in mice
Geisshüsler et al. Amphiphilic Cyclodextrin‐Based Nanoparticulate Vaccines Can Trigger T‐Cell Immune Responses
US20100209452A1 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
Dwivedi et al. Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome
THOMAS et al. Sommaire du brevet 2868123
THOMAS et al. Patent 2868123 Summary
RU2731509C1 (ru) Способ получения аллергоида на основе пчелиного яда для проведения аллерген-специфической иммунотерапии
EP1716866A1 (fr) Proteoliposomes et leurs derives utilises comme adjuvants inducteurs de reponse cytotoxique et formulations resultantes
Peine Formulation of Particulate-based Immunomodulatory Therapeutics for the Treatment of Diseases

Legal Events

Date Code Title Description
EEER Examination request